



Crucell will be holding a Conference Call regarding this announcement

on

Thursday 16 August 2001

at

16:00 Central European time

15:00 London time

10:00 New York time

Please call: + 31 (0)20 – 531 5881

10 minutes prior to commencement and state that you are calling for
Crucell's Conference Call

The conference call will be recorded and replay is available until
August 24, 2001

Dial-in number: + 31 (0)70 315 4300

Code replay: **91 91 58**

Crucell N.V. (Euronext Amsterdam: CRUC, Nasdaq: CRXL), a leading biotechnology company, discovers and develops huMADE™ biopharmaceutical products that utilize the human immune system to combat disease. Crucell's human technology platforms, PER.C6™ and MAbstract™, are applied to discover drug targets and to develop antibody-based products for treatment of cancer, inflammatory diseases, and vaccine products for the prevention and treatment of influenza and other infectious diseases.

Crucell enters into licensing or co-development agreements for its in-house products, or starts new target discovery and product development programs with partners.

PER.C6™ is made available under exclusive or non-exclusive license agreements for production of antibodies, proteins, vaccines and gene therapy products. Crucell has currently signed 18 agreements with major pharmaceutical and biotechnology companies for its PER.C6™ technology.

Crucell has a listing on NASDAQ and Euronext, and has raised 144 million Euro in its October 2000 IPO. Crucell's head office is located in Leiden, the Netherlands. Crucell employs approximately 130 people in its facilities in Leiden and Utrecht.